招商证券(06099)2025年度归母净利润123亿元，同比增长18.43% 【重大事项】 国恩科技(02768)1月27日至1月30日招股 预计2月4日上市 鸣鸣很忙(01768)：香港公开发售获1899.49倍认购 每股发售价236.6港元 威胜控股(03393)建议分拆惟远能源并于港交所主板独立上市 安踏体育(02020)拟约15.06亿欧元收购PUMA SE的29.06%股权 英矽智能(03696)与齐鲁制药达成超过9.31亿港元的药物研发合作 加速心血管与代谢类疾病创新疗法开 发 华检医疗(01931)子公司成功研发尼帕病毒检测双平台解决方案及集团AI医疗战略升级 【财报数据】 康希诺生物(06185)预期2025年度取得归母净利润2450万元到2900万元 同比扭亏为盈 中海物业(02669)发盈警 预期2025年股东应占溢利同比下跌9-10% 中国中药(00570)发盈警 预计2025年度净亏损约3.5亿至5亿元 【股债融资】 海通恒信(01905)发布2025年业绩快报 年度溢利14.25亿元 同比减少5.8% 国泰海通(02611)发盈喜 预期年度归母净利约275.33亿元到280.06亿元 ...

Core Viewpoint - Hansoh Pharmaceutical (03692) has experienced a decline of over 5%, currently trading at HKD 38.48, with a transaction volume of HKD 69.45 million [1] Group 1: Financial Actions - The company announced a proposal to issue HKD 4.68 billion zero-coupon convertible bonds maturing in 2033, with a conversion price of HKD 57.39, representing a premium of approximately 42.62% over the previous trading day's closing price [1] - The expected net proceeds from the bond issuance are approximately HKD 4.64 billion [1] Group 2: Use of Proceeds - Approximately 65% of the proceeds will be allocated for drug research and development and licensing [1] - About 25% will be used for the construction of new research and development centers and production lines, as well as upgrading existing facilities [1] - The remaining 10% will be designated for working capital and other general corporate purposes [1]

Core Viewpoint - Hansoh Pharmaceutical (03692) has seen its stock price decline over 5%, currently trading at HKD 38.48 with a transaction volume of HKD 69.45 million [1] Group 1: Financial Actions - The company announced a proposal to issue zero-coupon convertible bonds worth HKD 4.68 billion, maturing in 2033, with a conversion price of HKD 57.39, representing a premium of approximately 42.62% over the previous trading day's closing price [1] - The expected net proceeds from the bond issuance are approximately HKD 4.64 billion [1] Group 2: Use of Proceeds - About 65% of the proceeds will be allocated for drug research and development and licensing [1] - Approximately 25% will be used for the construction of new research and development centers and production lines, as well as upgrading existing facilities [1] - The remaining 10% will be designated for working capital and other general corporate purposes [1]

翰森制药(03692)发布公告，于2026年1月26日(交易时段后)，公司与经办人订立认购协议。根据认购协 议，(其中包括)公司已有条件同意向经办人(或根据经办人指示)发行，而经办人亦已有条件与公司商定 个别而非共同认购和支付债券，惟须遵守认购协议所载的若干条件。 公司将向维也纳证券交易所营运的Vienna MTF申请批准债券上市及买卖。公司亦将向联交所申请批准 换股股份在联交所上市及买卖。 债券可依照条款和条件转换成换股股份。假设债券按每股股份的初始换股价57.39港元悉数转换，且公 司概无进一步发行股份，债券将可转换成8154.73万股股份(总面值约815港元)，占公司于本公告日期已 发行股本约1.35%，并占经债券悉数转换时发行换股股份扩大后的公司于本公告日期已发行股本约 1.33%。于转换债券时予以发行的换股股份将在所有方面与相关登记日当时已发行股份享同等地位，并 享有相同的权利和特权。 经扣除佣金及其他相关费用后，预计债券所得款项净额约46.4亿港元，按照初始换股价计算，每股换股 股份的发行价格净额约56.90港元。 ...

Core Viewpoint - Hansoh Pharmaceutical (03692) has announced a subscription agreement with an underwriter, allowing the company to issue convertible bonds, which can be converted into shares at a specified price, potentially raising significant capital [1] Group 1: Subscription Agreement Details - The company has conditionally agreed to issue bonds to the underwriter, who will subscribe individually rather than collectively, subject to the terms of the agreement [1] - The bonds can be converted into shares at an initial conversion price of HKD 57.39 per share, potentially resulting in the issuance of approximately 81.55 million shares, representing about 1.35% of the company's existing share capital as of the announcement date [1] - The net proceeds from the bond issuance are expected to be approximately HKD 4.64 billion, with a net issue price of about HKD 56.90 per share based on the initial conversion price [1] Group 2: Listing and Trading - The company plans to apply for the listing and trading of the bonds on the Vienna MTF operated by the Vienna Stock Exchange [1] - Additionally, the company will seek approval for the listing and trading of the converted shares on the Hong Kong Stock Exchange [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 本公告僅供參考，並不構成提呈收購、購買或認購本公司證券之邀請或招攬，或訂立協議以作 出上述行動之邀請，亦不應被視為提呈收購、購買或認購本公司任何證券之邀請。 本公告及其所載資料不會直接或間接於或向美國（包括美國的領土及屬地、任何州及哥倫比亞 特區）發佈。本公告及其所載資料並不構成在美國境內購買、認購或出售證券的任何要約或招 攬或其組成部分。本公告中所述的證券並無亦不會根據1933年美國證券法（經不時修訂）（「美國 證券法」）或美國的任何州或其他司法管轄區的證券法律登記。本公告中所述的證券將根據美國 證券法S規例（「S規例」）在美國境外發售和出售，除非已進行登記或獲豁免遵守美國證券法的 登記規定，否則該等證券不得在美國境內發售或出售。本公告中所述的證券將不會於美國境內 或該等發售受到限制或禁止的任何其他司法管轄區境內公開發售。本公告或其所載資料並非金 錢、證券或其他對價的招攬，而倘為回應本公告或其所載資料而 ...

Investment Rating - The report maintains a "Recommended" investment rating for the pharmaceutical industry as of January 26, 2026 [1] Core Insights - The report emphasizes the importance of supply-side variables, particularly the operating rates of raw material drugs, and highlights the potential for price recovery in the antibiotic market due to changes in competition and supply dynamics [2] - Multi-departmental policy support is enhancing the value positioning of pharmacies, transforming them from mere sales points to comprehensive health service platforms [3] - The trend of Chinese innovative drugs going global is gaining momentum, with significant licensing deals and the need for continuous clinical data validation to support long-term investment confidence [4] - Major companies are increasingly investing in the small nucleic acid field, which is expected to accelerate the development of the supporting industrial chain [5] - A new pricing system for GLP-1 drugs is forming in China, with expectations for market growth driven by a large patient population [6] - The report highlights the market value of oral autoimmune drugs, with promising clinical trial results for new treatments [7] Summary by Sections 1. Pharmaceutical Market Tracking - The pharmaceutical industry outperformed the CSI 300 index by 0.23 percentage points in the last week, ranking 27th among 31 sectors [20] 2. Pharmaceutical Sector Trends and Valuation - The pharmaceutical sector index increased by 4.98% over the past month, outperforming the CSI 300 index by 3.21 percentage points [37] - The current PE (TTM) for the pharmaceutical sector is 38.51, above the five-year historical average of 31.06 [43] 3. Recent Research Achievements - The report includes various deep-dive studies on topics such as the growth of the blood products industry and the impact of policies on inhalation formulations [45] 4. Recent Industry Policies and News - Recent policies include the approval of numerous medical device registrations and the promotion of high-quality development in the pharmaceutical retail sector [46][48]

Core Viewpoint - The innovative drug sector experienced a significant surge in 2025, with multiple innovative drug ETFs seeing annual gains exceeding 50% and several companies doubling their stock prices. However, since September 2025, both A-shares and Hong Kong stocks in this sector have faced notable corrections, with some stocks nearly halving in value. The market is now focusing on the quality of business development (BD) transactions rather than just their existence [5][6][7]. Group 1: Market Trends and Reactions - In 2025, the innovative drug sector's market capitalization reached approximately 3 trillion yuan, driven by significant BD transactions [5]. - The market's initial enthusiasm for BD transactions has waned, as investors realize that these transactions often provide only temporary cash flow improvements rather than sustainable profitability [6][7]. - The focus has shifted from merely having BD transactions to assessing their quality, which is crucial for investment decisions in innovative drugs [8]. Group 2: High-Quality BD Transactions - High-quality BD transactions are characterized by three main anchors: the certainty of target value realization, the feasibility of milestone payments, and the strength of the partner company, particularly multinational pharmaceutical firms [10]. - An example of a successful BD transaction is the collaboration between Rongchang Biopharmaceutical and AbbVie, which led to a significant stock price increase due to the validated target of the drug involved [11][13]. - Conversely, a BD transaction involving Haikang Pharmaceutical and AirNexis did not yield positive market reactions due to the lower credibility of the partner and the insufficient cash component of the upfront payment [18][20][21]. Group 3: Company Performance and Investment Opportunities - Companies like Baijie and Hengrui have shown promising performance, with Baijie leading in innovative drug revenue and expected to turn profitable in 2025, while Hengrui has successfully transitioned to an innovative drug-focused business model [34][37]. - Hansoh Pharmaceutical has also achieved profitability, with a significant portion of its revenue coming from innovative drugs, indicating a successful transformation [40]. - Companies such as Xinda Biopharmaceutical and Sanofi have potential for future profitability, with Xinda expected to launch a promising product that could significantly impact its financials [43][48]. Group 4: Selection Criteria for Investment - The selection process for investment should involve identifying companies with a high proportion of innovative drug revenue (at least 50%), assessing their profitability, and evaluating the quality of their BD collaborations and global competitiveness of their pipelines [30][31]. - The analysis of the top 15 companies by innovative drug revenue shows that 13 have over 50% of their revenue from innovative drugs, highlighting a strong focus on innovation within the sector [32]. Group 5: Future Outlook - The innovative drug industry remains attractive, but the market's valuation criteria have evolved to prioritize the quality of BD transactions and the underlying performance of companies [58]. - Continuous monitoring of companies' clinical pipeline progress and BD transaction outcomes will be essential for assessing future market activity and investment potential [58].

Investment Rating - The report maintains an "Overweight" rating for the innovative pharmaceutical and medical device industry chain [5][7]. Core Viewpoints - Continuous support policies are being implemented, which are expected to benefit innovative surgical projects and retail pharmacy chains [2][5]. - The report highlights the high growth potential in innovative pharmaceuticals, recommending companies such as Heng Rui Medicine, Hansoh Pharmaceutical, Sanofi, Kelun Pharmaceutical, and Enhua Pharmaceutical for overweight ratings [5][7]. - The report also emphasizes the recovery of the CXO and upstream pharmaceutical sectors, recommending companies like WuXi AppTec, WuXi Biologics, and others for overweight ratings [5][7]. Summary by Sections Innovative Pharmaceuticals and Medical Devices - The report continues to recommend the innovative pharmaceutical sector, indicating a potential revaluation of companies like Heng Rui Medicine and others [5][7]. - It highlights the gradual realization of innovative pipelines and the performance growth of Biopharma/Biotech companies, maintaining overweight ratings for several key players [5][7]. Market Performance - In the fourth week of January 2026, the A-share pharmaceutical sector underperformed the broader market, with the SW pharmaceutical and biological index declining by 0.4% compared to a 0.8% increase in the Shanghai Composite Index [9][14]. - The report notes that the pharmaceutical sector's premium level relative to the entire A-share market is currently at a normal level, with a relative premium rate of 65.4% as of January 23, 2026 [14][18]. Stock Recommendations - The report provides a detailed earnings forecast and valuation for various companies, maintaining overweight ratings for multiple firms across different segments, including innovative pharmaceuticals, medical devices, and consumer healthcare [8][5].

Investment Rating - The report maintains a positive investment rating for the pharmaceutical sector [5] Core Views - The report emphasizes three main investment themes for 2026: innovation, overseas expansion, and turnaround impulses, with a focus on BD2.0, small nucleic acids, and supply chain (CXO and upstream) [2][3] - The report suggests that the pharmaceutical sector is currently experiencing a rotation in investment focus, particularly in areas such as brain-computer interfaces, AI integration, small nucleic acids, and medical robotics [3] Summary by Sections Public Fund Holdings Update for Q4 2025 - Overall, the market value of public funds holding pharmaceutical stocks has decreased, with a total market value of 217.6 billion yuan, down by 51 billion yuan from the previous quarter [14] - The pharmaceutical sector's allocation in public funds is 7.96%, a decrease of 1.74 percentage points [19] - Chemical preparations remain the most heavily weighted sub-industry, while allocations to medical devices have increased [14][25] Market Review and Analysis - The pharmaceutical and biotechnology index decreased by 0.39% week-on-week, outperforming the CSI 300 index but underperforming the ChiNext index [1] - The total trading volume in the pharmaceutical sector was 554.24 billion yuan, accounting for 4.00% of the total trading volume in the Shanghai and Shenzhen markets [1] Investment Opportunities - The report identifies specific companies for potential investment, including: - CXO and innovative drug companies such as Tigermed, Zhaoyan New Drug, and Hai Si Ke, which have seen significant increases in fund holdings [16][38] - AI innovative drug companies like Jingtai Holdings and small nucleic acid firms such as Frontier Biotech and Yuyuan Pharmaceutical [3][38] - The report also highlights the importance of exploring CROs, essential drugs, and companies showing signs of bottoming out [3]